Experimental HCV Drugs
Experimental HCV Drugs
Achillion Reports Promising Data on All-oral Hepatitis C Regimen with ACH-3102
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 January 2013 00:00
- Written by Achillion Pharmaceuticals
Achillion Pharmaceuticals this week reported interim results from an ongoing Phase 2a study of an interferon-free regimen containing its once-daily NS5A inhibitor, ACH-3102, plus ribavirin. To date, the combination appears safe and shows potent activity against hepatitis C virus (HCV).
NEJM: Sofosbuvir, ABT-450, ABT-333 Look Good in Interferon-free Hepatitis C Regimens
- Details
- Category: HCV Treatment
- Published on Thursday, 03 January 2013 00:00
- Written by Liz Highleyman
Two 12-week, all-oral hepatitis C regimens -- Gilead's sofosbuvir, and Abbott's ABT-450 plus ABT-333, both with ribavirin -- produced promising cure rates in studies that have now been published in the January 3, 2013, New England Journal of Medicine.
AASLD 2012: Interferon Lambda Shows Good HCV Suppression, Better Tolerated than Interferon Alfa
- Details
- Category: HCV Treatment
- Published on Friday, 21 December 2012 00:00
- Written by Liz Highleyman
Pegylated interferon lambda works as well as pegylated interferon alfa for treating chronic hepatitis C, but with fewer side effects, according to studies presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. Researchers also reported the first data on interferon lambda in combination with direct-acting antivirals.
Phase 3 Studies Show Simeprevir plus Interferon/Ribavirin Cures Most Patients in 24 Weeks
- Details
- Category: HCV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Medivir
The hepatitis C virus (HCV) protease inhibitor simeprevir (formerly TMC435) plus pegylated interferon and ribavirin produced 12-week post-treatment sustained virological response (SVR12) for about 80% of genotype 1 chronic hepatitis C patients, and most could be cured with a 24-week course of therapy, according to data released by Medivir.
AASLD 2012: Telaprevir and VX-222 Pair Well in Interferon-free Regimens, VX-135 on the Horizon
- Details
- Category: HCV Treatment
- Published on Wednesday, 28 November 2012 00:00
- Written by Liz Highleyman
An all-oral regimen of telaprevir, VX-222, and ribavirin for 12 weeks was generally well-tolerated and produced sustained response in approximately 70% of previously untreated chronic hepatitis C patients, including those with hard-to-treat HCV subtype 1a, according to study findings presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this month in Boston.
More Articles...
- AASLD 2012: Simeprevir Safe and Effective for Hepatitis C Patients With Cirrhosis
- AASLD 2012: Interferon-free Faldaprevir + BI 207127 Safe and Effective for Hepatitis C Patients with Cirrhosis
- AASLD 2012: Sofosbuvir + GS-5885 + Ribavirin Shows High Early Response Rates for Genotype 1 HCV
- AASLD 2012: Sofosbuvir + Daclatasvir Dual Regimen Cures Most Patients with HCV Genotypes 1, 2, or 3
Web Design and Development by